2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 223

Clinical Predictors For Subcutaneous Power Doppler Signals Detected By Ultrasound in Hands Of Scleroderma Patients
Abstract Number: 2769

Clinical Remission After 52 Weeks Of Treatment Is a Predictor Of Adalimumab-Free Disease Control In Patients With Early Rheumatoid Arthritis: Hopeful 2 Study
Abstract Number: 735

Clinical Research Of Microscopic Polyangiitis Combined With Autoimmune Hemolytic Anemia
Abstract Number: 817

Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
Abstract Number: 2592

Clinical Significance Of Endothelial Vasodilator Function Evaluated By Endopat In Patients With Systemic Sclerosis
Abstract Number: 2633

Clinical Spectrum Of Cutaneous Vasculitis
Abstract Number: 217

Clinical Value Of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography In Patients With Adult-Onset Still’s Disease
Abstract Number: 756

Clinical Value Of Commonly-Measured Laboratory Tests In Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Abstract Number: 1781

Clinical Variation In Children With Mutations In MEFV
Abstract Number: 740

Clinically Apparent Arterial Thrombosis In Persons With Systemic Vasculitis
Abstract Number: 336

Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Abstract Number: 760

Cluster Analysis To Explore Clinical Subclassification Of Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss)
Abstract Number: 2842

Cochrane Systematic Review Of Self-Management Education Programs For People With Osteoarthritis
Abstract Number: 2608

Coeliac Disease In Scleroderma – Clinical Features, Frequency and Impact Of Screening In Scleroderma
Abstract Number: 1259

Cognitive Dysfunction In Childhood Systemic Lupus Erythematosus: Comparison Of Different Classification Criteria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].